LONDON – Kalvista Pharmaceutical has raised $33 million in a series B round, providing the means to diversify its plasma kallikrein inhibitors into the treatment of hereditary angioedema (HAE) while advancing its diabetic macular edema (DME) program to clinical proof of concept.